Senesco Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eloxx Pharmaceuticals Inc (ELOX)
Eloxx Pharmaceuticals Inc stock price live, this page displays NASDAQ ELOX stock exchange data. View the ELOX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eloxx Pharmaceuticals Inc real time stock price chart below.
What Is the Eloxx Pharmaceuticals Inc Stock Price Today?
The Eloxx Pharmaceuticals Inc stock price today is 17.450.
What Is the Stock Symbol for Eloxx Pharmaceuticals Inc?
The stock symbol for Eloxx Pharmaceuticals Inc is "ELOX."
What Stock Exchange Does Eloxx Pharmaceuticals Inc Trade On?
Eloxx Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eloxx Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eloxx Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELOX quote. (ISIN: US29014R3012)
What Is the Eloxx Pharmaceuticals Inc Stock Price Today?
The Eloxx Pharmaceuticals Inc stock price today is 17.450.
What Is the Stock Symbol for Eloxx Pharmaceuticals Inc?
The stock symbol for Eloxx Pharmaceuticals Inc is "ELOX."
What Stock Exchange Does Eloxx Pharmaceuticals Inc Trade On?
Eloxx Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eloxx Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eloxx Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELOX quote. (ISIN: US29014R3012)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.240
18.980
52 wk Range
0.000
23.400
ELOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.24018.980
52 wk Range
0.00023.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockELOX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
38.250
Upside
+119.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 8K Eloxx Pharmaceuticals Inc For: 11 August- Investing.com
Senesco Tech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Eloxx doses first patients in Alport syndrome trial- Investing.com
- Senesco Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Eloxx doses first patients in Alport syndrome trial
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 38.250
(+119.20% Upside)
Earnings
Latest Release
Aug 12, 2026
EPS / Forecast
-0.66 / --
Revenue / Forecast
-- / --
Compare ELOX to Peers and Sector
Metrics to compare | ELOX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELOXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −0.7x | −0.4x | |
PEG Ratio | - | 0.00 | 0.00 | |
Price/Book | 1.5x | 0.9x | 2.6x | |
Price / LTM Sales | - | 2.7x | 3.0x | |
Upside (Analyst Target) | 119.2% | 78.2% | 54.3% | |
Fair Value Upside | Unlock | 1.7% | 7.2% | Unlock |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Eloxx Pharma (ELOX) Stock Price Today?
The Eloxx Pharma stock price today is 17.450 USD.
What Stock Exchange Does Eloxx Pharma Trade On?
Eloxx Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eloxx Pharma?
The stock symbol for Eloxx Pharma is "ELOX."
What Is the Eloxx Pharma Market Cap?
As of today, Eloxx Pharma market cap is 70.440M USD.
What Is Eloxx Pharma's Earnings Per Share (TTM)?
The Eloxx Pharma EPS (TTM) is -2.844.
When Is the Next Eloxx Pharma Earnings Date?
Eloxx Pharma will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is ELOX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Eloxx Pharma Stock Split?
Eloxx Pharma has split 4 times.
How Many Employees Does Eloxx Pharma Have?
Eloxx Pharma has 10 employees.
What is the current trading status of Eloxx Pharma (ELOX)?
As of Sep 21, 2026, Eloxx Pharma (ELOX) is trading at a price of 17.450 USD, with a previous close of 17.450 USD. The stock has fluctuated within a day range of 17.240 USD to 18.980 USD, while its 52-week range spans from 0.000 USD to 23.400 USD.
What Is Eloxx Pharma (ELOX) Price Target According to Analysts?
The average 12-month price target for Eloxx Pharma is 38.250 USD, with a high estimate of 43 USD and a low estimate of 32 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +119.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.